Ascentage Pharma Buys Back 500,000 Shares Under Restricted Share Unit Plan

Deep News11-22 09:50

Ascentage Pharma (06855) has announced that on November 20, 2026, the trustee purchased a total of 500,000 existing shares on the market for the purposes of the 2022 Restricted Share Unit Plan, in order to satisfy restricted share units upon vesting.

The shares were acquired on-market to fulfill the company's obligations under its restricted share unit scheme, ensuring that vested units can be settled with existing shares.

This transaction reflects the company's ongoing commitment to its equity incentive program and the fulfillment of its obligations to participating employees under the plan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment